2010 Scrip 100 - Changes pharma can believe in?
This article was originally published in Scrip
Ian Schofield picks some of the most significant developments in the health policy and regulation circles in the first half of 2010 and explains their likely impacts on pharma. Barack Obama signed into law US health reform legislation, price cut fever spread across European markets and Japan's Chuikyo is mulling reforms to the country's drug reimbursement pricing system.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.